NASDAQ:PCRX Pacira BioSciences (PCRX) Stock Price, News & Analysis $36.48 0.00 (0.00%) As of 11/19/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Pacira BioSciences Stock (NASDAQ:PCRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pacira BioSciences alerts:Sign Up Key Stats Today's Range$36.48▼$36.4850-Day Range$24.08▼$36.4952-Week Range$18.80▼$36.67VolumeN/AAverage Volume1.07 million shsMarket Capitalization$1.46 billionP/E Ratio39.23Dividend YieldN/APrice Target$33.33Consensus RatingHold Company Overview Pacira BioSciences is a biopharmaceutical company focused on non-opioid approaches to pain management and related health needs. Its portfolio includes medicines and a device intended for use in surgical, musculoskeletal and other care settings. The company’s products include EXPAREL, a long-acting bupivacaine formulation used for postsurgical pain management; ZILRETTA, an extended-release corticosteroid injection for knee osteoarthritis pain; and the iovera system, which uses targeted cold to temporarily block peripheral nerves and relieve pain. Founded as Pacira Pharmaceuticals, the company adopted the Pacira BioSciences name in 2019. It markets products in the United States and uses commercial partners to support access in international markets.AI Generated. May Contain Errors. Read More Pacira BioSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScorePCRX MarketRank™: 1.79975261132 of 5 starsPacira BioSciences scored higher than 36% of companies evaluated by MarketBeat, and ranked 677th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingPacira BioSciences has received a consensus rating of Hold. The company's average rating score is 2.09, and is based on no strong buy ratings, 1 buy rating, 10 hold ratings, and no sell ratings.Downside RiskPacira BioSciences has a consensus price target of $33.33, representing about 8.6% downside from its current price of $36.48.Amount of Analyst CoveragePacira BioSciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pacira BioSciences' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth23.68% Earnings GrowthEarnings for Pacira BioSciences are expected to grow by 23.68% in the coming year, from $1.90 to $2.35 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacira BioSciences is 39.23, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.09.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacira BioSciences is 39.23, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.07.Price to Book Value per Share RatioPacira BioSciences has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.97% of the float of Pacira BioSciences has been sold short.Short Interest Ratio / Days to CoverPacira BioSciences has a short interest ratio ("days to cover") of 3.91, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pacira BioSciences has recently decreased by 21.40%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPacira BioSciences does not currently pay a dividend.Dividend GrowthPacira BioSciences does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 5 news articles for Pacira BioSciences this week, compared to 4 articles on an average week. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $217,920.00 in company stock.Percentage Held by Insiders6.40% of the stock of Pacira BioSciences is held by insiders.Percentage Held by Institutions99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pacira BioSciences' insider trading history. Receive PCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PCRX Stock News HeadlinesViatris completes $1.6B acquisitionNovember 19 at 1:14 PM | msn.comPacira BioSciences, Inc. Announces Management ChangesNovember 18 at 7:05 AM | marketscreener.comMYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.November 20 at 1:00 AM | Profits Run (Ad)Viatris Completes Acquisition of Pacira BioSciencesNovember 17 at 8:50 AM | prnewswire.comPacira BioSciences, Inc.(NasdaqGS:PCRX) dropped from S&P Composite 1500November 16, 2026 | marketscreener.comMViatris Reports Third-Quarter 2026 Financial ResultsNovember 5, 2026 | prnewswire.comINVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger – RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU?November 4, 2026 | globenewswire.comPCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its ShareholdersOctober 31, 2026 | businesswire.comSee More Headlines PCRX Stock Analysis - Frequently Asked Questions How have PCRX shares performed this year? Pacira BioSciences' stock was trading at $25.88 at the beginning of the year. Since then, PCRX shares have increased by 41.0% and is now trading at $36.48. How were Pacira BioSciences' earnings last quarter? Pacira BioSciences, Inc. (NASDAQ:PCRX) posted its earnings results on Thursday, November, 5th. The company reported $0.70 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.75 by $0.05. The business had revenue of $176.65 million for the quarter, compared to the consensus estimate of $181.94 million. Pacira BioSciences had a trailing twelve-month return on equity of 11.91% and a net margin of 5.08%. When did Pacira BioSciences IPO? Pacira BioSciences (PCRX) raised $64 million in an IPO on Wednesday, February 2nd 2011. The company issued 4,250,000 shares at a price of $14.00-$16.00 per share. Who are Pacira BioSciences' major shareholders? Top institutional investors of Pacira BioSciences include State Street Corp (5.35%), Goldman Sachs Group Inc. (3.70%), Gagnon Securities LLC (1.57%) and Bridge City Capital LLC (0.88%). Insiders that own company stock include Jonathan Slonin, Daryl Gaugler, Frank D Lee, Shawn Cross, Kristen Williams, Lauren Riker, Mark Froimson and Marcelo Bigal. View institutional ownership trends. How do I buy shares of Pacira BioSciences? Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pacira BioSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pacira BioSciences investors own include Gilead Sciences (GILD), Micron Technology (MU), Tesla (TSLA), Bristol Myers Squibb (BMY), NVIDIA (NVDA), Palo Alto Networks (PANW) and Alphabet (GOOG). Company Calendar Last Earnings11/05/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (8m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 PCRX's financial health is in the Green zone, according to TradeSmith. PCRX has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PCRX CIK1396814 Webwww.pacira.com Phone(813) 553-6680Fax302-655-5049Employees829Year Founded2006Price Target and Rating Average Price Target for Pacira BioSciences$33.33 High Price Target$36.50 Low Price Target$25.00 Potential Upside/Downside-8.6%Consensus RatingHold Rating Score (0-4)2.09 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)$0.93 Trailing P/E Ratio39.23 Forward P/E Ratio15.52 P/E GrowthN/ANet Income$7.03 million Net Margins5.08% Pretax Margin4.97% Return on Equity11.91% Return on Assets6.61% Debt Debt-to-Equity Ratio0.41 Current Ratio4.68 Quick Ratio3.65 Sales & Book Value Annual Sales$743.30 million Price / Sales1.97 Cash Flow$3.86 per share Price / Cash Flow9.46 Book Value$17.77 per share Price / Book2.05Miscellaneous Outstanding Shares40,095,000Free Float37,529,000Market Cap$1.46 billion OptionableOptionable Beta0.21 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:PCRX) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredI'm handing you this one freeDylan has tracked down the company behind what he calls the StarChip. It's already inside more than 10,000 Sta...Behind the Markets | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.